BIOPHARMA
ByIs Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Is Novo Nordisk’s Oral Wegovy Off to a Record Start? Early Prescription Surge Signals Strong Momentum
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded a robust debut,…
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion Investment to Advance Next-Generation Therapies
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing facility in Holly…
Can Johnson & Johnson’s $550 Million Vision Care Expansion Drive Local Growth and Innovation?
23 January 2026 Executive Summary Johnson & Johnson’s Vision Care division is advancing a major U.S. expansion project,…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its Next Growth Wave in Atopic Dermatitis?
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is set to report…
